Author: Tenforde, Mark W.; Patel, Manish M.; Ginde, Adit A.; Douin, David J.; Talbot, H. Keipp; Casey, Jonathan D.; Mohr, Nicholas M.; Zepeski, Anne; Gaglani, Manjusha; McNeal, Tresa; Ghamande, Shekhar; Shapiro, Nathan I.; Gibbs, Kevin W.; Files, D. Clark; Hager, David N.; Shehu, Arber; Prekker, Matthew E.; Erickson, Heidi L.; Exline, Matthew C.; Gong, Michelle N.; Mohamed, Amira; Henning, Daniel J.; Steingrub, Jay S.; Peltan, Ithan D.; Brown, Samuel M.; Martin, Emily T.; Monto, Arnold S.; Khan, Akram; Hough, C. Terri; Busse, Laurence; Lohuis, Caitlin C. ten; Duggal, Abhijit; Wilson, Jennifer G.; Gordon, Alexandra June; Qadir, Nida; Chang, Steven Y.; Mallow, Christopher; Gershengorn, Hayley B.; Babcock, Hilary M.; Kwon, Jennie H.; Halasa, Natasha; Chappell, James D.; Lauring, Adam S.; Grijalva, Carlos G.; Rice, Todd W.; Jones, Ian D.; Stubblefield, William B.; Baughman, Adrienne; Womack, Kelsey N.; Lindsell, Christopher J.; Hart, Kimberly W.; Zhu, Yuwei; Olson, Samantha M.; Stephenson, Meagan; Schrag, Stephanie J.; Kobayashi, Miwako; Verani, Jennifer R.; Self, Wesley H.
Title: Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States Cord-id: 1k0qpuys Document date: 2021_7_8
ID: 1k0qpuys
Snippet: BACKGROUND: As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes. METHODS: In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospit
Document: BACKGROUND: As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes. METHODS: In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid-19 and hospital-based controls who tested negative for SARS-CoV-2. RESULTS: Among 1210 participants, median age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine doses ≥14 days before illness onset) had been received by 45/590 (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18–49 years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%) than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%). CONCLUSION: During March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing Covid-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population.
Search related documents:
Co phrase search for related documents- acute respiratory illness and additional information: 1, 2, 3
- acute respiratory illness and additional study: 1
Co phrase search for related documents, hyperlinks ordered by date